J Korean Cancer Assoc.
2001 Apr;33(2):168-177.
Permanent Genotypic and Phenotypic Change of Prostate Cancer Cell Line LNCaP through Cellular Interactions with Prostate or Bone Fibroblasts in vitro or in vivo
- Affiliations
-
- 1Department of Urology, College of Medicine, The Catholic University of Korea, Seoul, Korea.
- 2Department of Urology, University of Virginia Health Science Center, Charlottesville, USA.
Abstract
-
PURPOSE: Cell-cell interactions determine normal prostate development and subsequent neoplastic transfor
mation. The progression of prostate cancer from androgen-dependent to androgen-independent states involves
multiple steps of genetic changes mediated by tumor-microenvironment interactions. To understand the epigenetic
factors that lead to progression, we studied if 1) androgen-dependent and non-metastatic LNCaP may interact
with prostate or bone fibroblasts under microgravity-simulated conditions in vitro. 2) LNCaP may interact with
prostate fibroblasts in vivo, and acquire androgen-independence and metastatic potential.
MATERIALS AND METHODS
The LNCaP sublines were generated as follows. 1) LNCaP cells were grown in vitro
either alone or with prostate or bone fibroblasts under microgravity-simulated conditions. 2) LNCaP cells were
grown in vivo as chimeric tumors with prostate fibroblasts. The LNCaP sublines were characterized by studies
of chromosomal analysis, comparative genomic hybridization and, in vivo tumorigenicity and metastatic potential.
RESULTS
In comparison to the parental LNCaP cells, the LNCaP sublines underwent permanent genotypic and
phenotypic changes manifested in androgen-independence and metastatic potential.
CONCLUSION
These results emphasize the importance of cell-cell interaction as a critical determinant that could
"induce" or "select" progenies favoring enhanced prostate cancer growth and progression. This concept favors
the development of toxic gene therapy targeting both prostate cancer epithelium and supporting bone stroma
for an effective eradication and prevention of prostate cancer bone metastasis.